It's nice to hear that You made it. Here's some more info about LDN treatment. For anyone interested...
Below studies can be found here
http://www.lowdosenaltrexone.org/NCI_Conference_Apr_2007.pdf
Personal experience with LDN for various cancers Burton Berkson, M.D., Ph.D
Dr. Berkson shared his experiences of LDN by demonstrating four interesting cases. The cases showed
that LDN is well tolerated and to date, some of the patients suffering from pancreatic cancer, B-Cell NonHodgkins Lymphoma are alive and well.
All of the mentioned patients received low dose naltrexone at
4.5mg Qhs, in addition to incorporating a healthy lifestyle, diet, supplemented with alpha-lipoic acid and
vitamins. The patients reported an improved quality of life and stable disease ranging up to 55 months on
naltrexone therapy. PET Scans showed notable improvements for several patients. In some cases where
CT showed no major change in tumor size, the PET scan did show a change in uptake after naltrexone
was administered which did correlate with clinical improvement. There was not a significant change in
the sizes of the tumors, but LDN played a major role in stopping the activity of the disease.
II. Clinical experience with LDN in Crohns Disease/ Pancreatic Cancer Jill Smith, M.D.
Treatment: The patients who met inclusion criteria were treated with naltrexone 4.5 mg qhs for 12 weeks
followed by a 4-week follow-up off medication. The subjects stayed on baseline medications during study
at the same doses and infliximab was not allowed. In order to evaluate a response, blood tests for
inflammatory markers, CDAI scores, and quality life surveys were evaluated monthly. A response to
treatment occurred when the CDAI scores decreased by 70 points, and remission was categorized with a
score of 150 or less.
Results: 17 subjects completed the pilot study. 2 subjects with open fistulas had closure. 2 subjects
discontinued routine medication and one flared. The other did well and continued on naltrexone alone.
Overall, after LDN therapy, there was a statistically significant improvement in CDAI scores, improved
Quality of Life, increased chance of remission, decreased blood inflammatory markers and minimal side
effects.
Advantages of Naltrexone: (1) May be administered orally, (2) Down-regulates but does not eliminate
proinflammatory cytokines, (3) few side effects, (4) once a day dosing, (5) Cost effective.
III. Opioid Growth Factor (OGF) in Pancreatic Cancer Jill Smith, M.
Results: To date, there are 23 patients enrolled and treated. 4 patients were evaluated and not enrolled.
OGF was well tolerated. Quality of life appears better than chemotherapy. The weeks of treatment ranged
from 1-27 weeks. Thus far, 2 patients are alive on therapy; one regression of primary tumor, some
decreases in CA19-9 noted and there is a stabilization of disease.
Conclusion: Treatment of pancreatic cancer is a challenge. Opioid growth factor inhibits growth of
pancreatic cancer in culture, mice and humans. OGF appears to improve survival in human subject and
improve Quality of Life. The combination therapy with gemcitabine has potential with promising results.
More research is needed in the area of opioids and treatment of various cancers.
More can be read here
http://www.lowdosenaltrexone.org/ldn_trials.htm#Recent
LDN treatment on Chron's disease
http://www.clinicaltrials.gov/ct2/show/NCT00715117?term=crohns+smith&rank=2
http://www.ncbi.nlm.nih.gov/pubmed/17222320?dopt=Abstract
How an Overlooked Drug Relieves Cancer, AIDS, MS, and Immune System Disorders for a Dollar a Day
http://www.googleldn.com/